Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

InterMune, Roche form new danoprevir deal valued at $175mm

Executive Summary

Four years after forming a global development and US co-promotion agreement with Roche for its hepatitis C protease inhibitor danoprevir, InterMune Inc. (respiratory and infectious disease therapeutics) has decided to cease its investment in the drug candidate, thereby terminating that 2006 deal. Roche now has sole ownership, holding worldwide development and commercialization rights.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Product Purchase

Related Companies

UsernamePublicRestriction

Register